# Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

> **NCT02195011** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 26 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DEVICE:** SIR-Spheres
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02195011
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2017-06-04
- **Final completion:** 2017-06-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195011, "Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02195011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*